Jinlei Bian

2.5k total citations
98 papers, 1.9k citations indexed

About

Jinlei Bian is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Jinlei Bian has authored 98 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 22 papers in Oncology and 17 papers in Organic Chemistry. Recurrent topics in Jinlei Bian's work include Ubiquitin and proteasome pathways (15 papers), Cancer, Hypoxia, and Metabolism (15 papers) and Protein Degradation and Inhibitors (14 papers). Jinlei Bian is often cited by papers focused on Ubiquitin and proteasome pathways (15 papers), Cancer, Hypoxia, and Metabolism (15 papers) and Protein Degradation and Inhibitors (14 papers). Jinlei Bian collaborates with scholars based in China, Russia and Tajikistan. Jinlei Bian's co-authors include Zhiyu Li, Jubo Wang, Xi Xu, Qidong You, Xiaojin Zhang, Ying Meng, Lei Li, Pengfei Xu, Haopeng Sun and Yifan Feng and has published in prestigious journals such as Nature Communications, Biomaterials and Applied and Environmental Microbiology.

In The Last Decade

Jinlei Bian

90 papers receiving 1.8k citations

Peers

Jinlei Bian

ONCOL

PRM

Quan Zhang China

Chuan Shih United States

Lijun Sun United States

Jinyun Dong China

Gregory D. Vite United States

Lai‐Ming Ching New Zealand

Yahui Ding China

Qing Cheng Sweden

Jubo Wang China

Esther C. Y. Woon United Kingdom

Quan Zhang China

Jinlei Bian

1.3k ×1.2

528 ×1.2

390 ×1.0

ONCOL

623 ×2.5

414 ×2.0

PRM

Citations per year, relative to Jinlei Bian Jinlei Bian (= 1×) peers Quan Zhang

Countries citing papers authored by Jinlei Bian

Since Specialization

Citations

This map shows the geographic impact of Jinlei Bian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinlei Bian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinlei Bian more than expected).

Fields of papers citing papers by Jinlei Bian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinlei Bian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinlei Bian. The network helps show where Jinlei Bian may publish in the future.

Co-authorship network of co-authors of Jinlei Bian

This figure shows the co-authorship network connecting the top 25 collaborators of Jinlei Bian. A scholar is included among the top collaborators of Jinlei Bian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinlei Bian. Jinlei Bian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Mengdi, Yuanyuan Lei, Tao Yang, et al.. (2025). Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement. Pharmacological Research. 215. 107706–107706. 1 indexed citations

Skvortsov, Dmitry A., В. А. Чертков, Борис Н. Тарасевич, et al.. (2025). Synthesis and in vitro study of a novel catechol with a hydantoin core. Medicinal Chemistry Research. 34(7). 1557–1575.

Huang, Li, Yang Xue, Yunhao Lu, et al.. (2025). The Remineralization Potential of Resveratrol and Cucurbit[ n ]uril. Journal of Dental Research. 105(3). 332–341.

Zhang, Xiankang, Yifang Liu, Yifan Xu, et al.. (2025). Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting. Journal of Medicinal Chemistry. 68(4). 4929–4950. 1 indexed citations

Shen, Pei, et al.. (2024). Design strategies and recent development of bioactive modulators for glutamine transporters. Drug Discovery Today. 29(2). 103880–103880. 4 indexed citations

Guo, Huimin, et al.. (2024). Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia. Journal of Medicinal Chemistry. 67(8). 6687–6704.

Чертков, В. А., Борис Н. Тарасевич, В. А. Тафеенко, et al.. (2024). Synthesis of Nitro Derivatives of Pyrocatechin as Potential Biologically Active Precursors. ChemistrySelect. 9(29). 1 indexed citations

Yan, Tian‐Hao, Wei Yuan, Lianbing Zhang, et al.. (2024). Natural flavonoid glycoside-based self-assembled nanoparticles for synergistic antibacterial activity and improved antioxidant properties. Journal of Drug Delivery Science and Technology. 105. 106583–106583. 1 indexed citations

Tong, Chao, et al.. (2024). Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions. European Journal of Medicinal Chemistry. 267. 116212–116212. 17 indexed citations

10.

Tian, Yucheng, Kang Liu, Dongdong Wu, et al.. (2024). The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364. European Journal of Medicinal Chemistry. 268. 116275–116275. 2 indexed citations

11.

Yu, Bin, Jing Zhang, Yucheng Tian, et al.. (2023). Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry. 259. 115711–115711. 2 indexed citations

12.

Zhang, Di, Tian Chen, Yuqing Zhang, et al.. (2023). Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer. European Journal of Medicinal Chemistry. 257. 115490–115490. 2 indexed citations

13.

Li, Wen, Jiali Huang, Xi Yang, et al.. (2023). Tumor-targeted metabolic inhibitor prodrug labelled with cyanine dyes enhances immunoprevention of lung cancer. Acta Pharmaceutica Sinica B. 14(2). 751–764. 9 indexed citations

14.

Liu, Dongyu, Bin Yu, Xin‐Yuan Guan, et al.. (2023). Discovery of a photoactivatable dimerized STING agonist based on the benzo[b]selenophene scaffold. Chemical Science. 14(15). 4174–4182. 12 indexed citations

15.

Tian, Kun, et al.. (2023). Reversal of hepatic fibrosis by the co-delivery of drug and ribonucleoprotein-based genome editor. Biomaterials. 298. 122133–122133. 12 indexed citations

16.

Xu, Xi, Di Zhang, Min Wang, et al.. (2022). Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles. European Journal of Medicinal Chemistry. 236. 114337–114337. 9 indexed citations

17.

Ding, Hong, Yuan‐Qing Li, Wen Xu, et al.. (2021). Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer. Bioorganic & Medicinal Chemistry. 52. 116512–116512. 14 indexed citations

18.

Han, Jie, Yucheng Tian, Liang Yu, et al.. (2020). Discovery of novel USP8 inhibitors via Ubiquitin-Rho-110 fluorometric assay based high throughput screening. Bioorganic Chemistry. 101. 103962–103962. 9 indexed citations

19.

Bian, Jinlei, et al.. (2017). Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile. European Journal of Medicinal Chemistry. 129. 27–40. 39 indexed citations

20.

Xu, Xi, Lei Li, Jubo Wang, et al.. (2017). Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents. European Journal of Medicinal Chemistry. 143. 1325–1344. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact